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Abstract: The feasibility of targeting drugs to hair follicles by a combination of microencapsulation and 
iontophoresis has been evaluated. Minoxidil sulphate (MXS), which is used in the treatment of alopecia, 
was selected as a relevant drug with respect to follicular penetration. The skin permeation and 
disposition of MXS encapsulated in chitosan microparticles (MXS-MP) was evaluated in vitro after 
passive and iontophoretic delivery. Uptake of MXS was quantified at different exposure times in the 
stratum corneum (SC) and hair follicles. Microencapsulation resulted in increased (6-fold) drug 
accumulation in the hair follicles relative to delivery from a simple MXS solution. Application of 
iontophoresis enhanced follicular delivery for both the solution and the microparticle formulations. It 
appears, therefore, that microencapsulation and iontophoresis can act synergistically to enhance 
topical drug targeting to hair follicles. 
 
Response to Reviewers: Responses to Reviewer #1: 
 
The paper concerns the application of iontophoresis associated with microparticles to improve 
follicular delivery of minoxidil. The paper is well organized, however some important details are 
missing and are of outermost importance to understand and comment the data obtained. Additionally 
the discussion is very meager and does not try to elucidate the mechanisms that could justify the 
results obtained. 
 
R: The points raised by the reviewer have been addressed as detailed below and the Discussion has 
been modified accordingly. The changes made have been highlighted in the revised manuscript. 
 
 
1. More details on the particles should be given. From the previously published data (ref 2 of the 
paper) it seems that the particles quickly swell as soon as they are put in contact with EtOH:H2O. What 
is the consequence of the swelling? These details should be given. What about the impact of 
iontophoresis on these particles? 
 
R: Details of the particles’ characteristics have been provided in the manuscript. The particles do 
indeed swell quickly in contact with the ethanol/water (from 3.0 µm to 5.7 µm) and this permits the 
sustained release of MXS to be achieved. We envisage that the swollen microparticles remain on skin 
surface, and that only drug that has been released from the carriers is able to cross the skin. However, 
the microparticles appear to accumulate in follicular openings, a conclusion supported by the 
enhanced recovery of MXS from these appendageal structures. The points have been highlighted in the 
revised manuscript (see Discussion, highlighted in yellow, p. 7-8). 
With respect to iontophoresis, it seems likely that the microparticles used are too large to be 
transported, to any significant extent, through the skin by the applied electric field.  However, because 
the follicles are low resistance pathways for the movement of charge across the skin, we speculate that 
iontophoresis can quickly and efficiently target MXS-MP to follicular openings, and that MXS is then 
released from the microparticles directly into the infundibulum (p. 9).  
 
 
2. In the paper the release of the drug from the MP is completely overlooked. This should be presented 
(or, if already published, details should be added) and the data discussed also considering this aspect. 
Is there non encapsulated drug? If yes, what's the contribution of the non encapsulated drug? What's 
the % of drug released after 3, 6, 12, 24 h? 
 
R: Drug release data are included in the Discussion (p. 8). As stated above, we believe that only drug 
that has been released from the microparticles is able to cross the skin (with or without 
iontophoresis); however, because iontophoresis ‘targets’ the MXS-MP to the follicles, increased levels 
of drug are made available to be taken up and absorbed at these specific sites (p.9). Our previously 
published work shows that approximately 30%, 53%, 72% of MXS were released from the 
microparticles after 3, 6 and 12 h, respectively [2].  
 
 
3. In Figure 2, when considering the receptor solution (MP and ionto) a 25x enhancement is obtained. 
The authors should discuss this result. What's the impact of iontophoresis on MPs? Electrorepulsion? 
Electroosmosis? Effect on drug release? Apparently this strategy could be useful to increase the 
transdermal delivery? 
 
R: Because the chitosan-based MXS-MP have a positive zeta potential [2], it was hypothesised that an 
iontophoretic current would enhance follicular localisation when the drug delivery system was 
associated with the anode (and also permitting advantage to be taken of the anode-to-cathode 
electroosmotic flow typically established across the net negatively-charged skin membrane). But, as 
already stated, the swollen, 5.9 µm microparticles are unlikely themselves to penetrate the follicles and 
only released MXS diffuses into and through the skin. At the pH of the formulation (pH ~5.5), MXS is 
90% non-ionized suggesting that its enhanced, electrotransport-mediated delivery will be due to a 
combination of electrorepulsion and electroosmosis [16]. From a practical standpoint, for the topical 
treatment of alopecia, where a local effect is desired with as little transdermal exposure as possible, the 
judicious selection of current density and application time in vivo is required for optimal therapy (p. 
8). 
 
 
4. Is there any more general conclusion that could be drawn on the association of MP and 
iontophoresis? The use of iontophoresis on MP accumulates 3.9 µg/cm2, while on a simple solution the 
amount is 2.4 µg/cm2. Is the difference statistically significant? It's worth it? 
 
R: A general conclusion about the association of MP and iontophoresis has been given (p.10). The 
amount of MXS taken up into follicles after iontophoresis of microparticles was significantly greater (p 
< 0.05) compared to that from a simple MXS solution. We consider that this significant enhancement in 
MXS follicular retention together with the sustained release of the drug when iontophoresis is 
combined with microparticles represents a potentially useful strategy for the targeted treatment of 
alopecia. 
 
 
5. Second highlights: please add "after 6 hours" since this is not true for other application times. 
 
R: The information was added. 
  
 
 
Responses to Reviewer #2: 
 
- This is a very well-written and structured research article which contains interesting data for 
researchers and scientists in the area of dermal and transdermal drug delivery. The investigation of the 
combination of chitosan microparticles and iontophoresis is an intelligent approach. The experimental 
design is sophisticated and neatly arranged. Therefore, it is a valuable and excellent contribution to the 
journal. Since these are interesting results and the main focus of the journal Colloids and Surfaces B: 
Biointerfaces is the impact of colloid and interfacial phenomena on biological systems the authors 
could discuss the causes and theoretical fundamentals of the significant accumulation of the chitosan 
microparticles also after the application of iontophoresis in the hair follicles. The physicochemical 
properties of the chitosan particles and their impact on the preferential follicular penetration might be 
taken into account for this discussion in more detail. 
 
R: The authors thank the reviewer for these positive comments. The Discussion has now been 
supplemented (see yellow highlighted text) with further information concerning how the preferential 
follicular penetration of the drug is influenced by the physicochemical properties of the microparticles 
and of the drug (i.e., the swelling of microparticles in contact with the ethanol/water formulation, the 
sustained MXS release achieved, and MXS ionization at the pH of formulation).  
 
 
- One comment on the physical stability of these particles might be added in section 2.3. How and to 
which amount were the microparticles suspended in the ethanol:water mixture? 
 
R: Supplementary information has been added to section 2.3 in response to this comment (p. 5). The 
drug loading efficiency of the chitosan microparticles was at least 80%. The amount of chitosan 
relative to MXS was 2:1 (w/w); 7.5 g of the MXS-loaded microparticles were suspended in 93 mL of 
ethanol/water (6:4 v/v), creating a formulation containing 2% w/v of MXS. 
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Dear Professor Danino, 
We are grateful for the Reviewers’ comments and suggestions. In response to their 
comments, we have implemented changes to the manuscript. These changes are highlighted in 
the manuscript and referenced in the letter of rebuttal, in which we have listed the Reviewers’ 
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We thank you for the opportunity to submit our revised manuscript and look forward 
to hearing from you soon. 
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Reviewer 1 
The paper concerns the application of iontophoresis associated with microparticles to 
improve follicular delivery of minoxidil. The paper is well organized, however some important 
details are missing and are of outermost importance to understand and comment the data 
obtained. Additionally the discussion is very meager and does not try to elucidate the 
mechanisms that could justify the results obtained. 
The points raised by the reviewer have been addressed as detailed below and the 
Discussion has been modified accordingly. The changes made have been highlighted in the 
revised manuscript. 
 
1. More details on the particles should be given. From the previously published data (ref 2 of 
the paper) it seems that the particles quickly swell as soon as they are put in contact with 
EtOH:H2O. What is the consequence of the swelling? These details should be given. What 
about the impact of iontophoresis on these particles? 
Details of the particles’ characteristics have been provided in the manuscript. The 
particles do indeed swell quickly in contact with the ethanol/water (from 3.0 µm to 5.7 µm) 
and this permits the sustained release of MXS to be achieved. We envisage that the swollen 
microparticles remain on skin surface, and that only drug that has been released from the 
carriers is able to cross the skin. However, the microparticles appear to accumulate in 
follicular openings, a conclusion supported by the enhanced recovery of MXS from these 
appendageal structures. The points have been highlighted in the revised manuscript (see 
Discussion, highlighted in yellow, p. 7-8). 
With respect to iontophoresis, it seems likely that the microparticles used are too 
large to be transported, to any significant extent, through the skin by the applied electric field.  
However, because the follicles are low resistance pathways for the movement of charge 
across the skin, we speculate that iontophoresis can quickly and efficiently target MXS-MP to 
follicular openings, and that MXS is then released from the microparticles directly into the 
infundibulum (p. 9).  
 
2. In the paper the release of the drug from the MP is completely overlooked. This should be 
presented (or, if already published, details should be added) and the data discussed also 
considering this aspect. Is there non encapsulated drug? If yes, what's the contribution of the 
non encapsulated drug? What's the % of drug released after 3, 6, 12, 24 h? 
Drug release data are included in the Discussion (p. 8). As stated above, we believe 
that only drug that has been released from the microparticles is able to cross the skin (with or 
without iontophoresis); however, because iontophoresis ‘targets’ the MXS-MP to the follicles, 
increased levels of drug are made available to be taken up and absorbed at these specific 
sites (p.9). Our previously published work shows that approximately 30%, 53%, 72% of MXS 
were released from the microparticles after 3, 6 and 12 h, respectively [2].  
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3. In Figure 2, when considering the receptor solution (MP and ionto) a 25x enhancement is 
obtained. The authors should discuss this result. What's the impact of iontophoresis on MPs? 
Electrorepulsion? Electroosmosis? Effect on drug release? Apparently this strategy could be 
useful to increase the transdermal delivery? 
Because the chitosan-based MXS-MP have a positive zeta potential [2], it was 
hypothesised that an iontophoretic current would enhance follicular localisation when the 
drug delivery system was associated with the anode (and also permitting advantage to be 
taken of the anode-to-cathode electroosmotic flow typically established across the net 
negatively-charged skin membrane). But, as already stated, the swollen, 5.9 µm 
microparticles are unlikely themselves to penetrate the follicles and only released MXS 
diffuses into and through the skin. At the pH of the formulation (pH ~5.5), MXS is 90% non-
ionized suggesting that its enhanced, electrotransport-mediated delivery will be due to a 
combination of electrorepulsion and electroosmosis [16]. From a practical standpoint, for the 
topical treatment of alopecia, where a local effect is desired with as little transdermal 
exposure as possible, the judicious selection of current density and application time in vivo is 
required for optimal therapy (p. 8). 
 
4. Is there any more general conclusion that could be drawn on the association of MP and 
iontophoresis? The use of iontophoresis on MP accumulates 3.9 µg/cm2, while on a simple 
solution the amount is 2.4 µg/cm2. Is the difference statistically significant? It's worth it? 
A general conclusion about the association of MP and iontophoresis has been given 
(p.10). The amount of MXS taken up into follicles after iontophoresis of microparticles was 
significantly greater (p < 0.05) compared to that from a simple MXS solution. We consider 
that this significant enhancement in MXS follicular retention together with the sustained 
release of the drug when iontophoresis is combined with microparticles represents a 
potentially useful strategy for the targeted treatment of alopecia. 
 
5. Second highlights: please add "after 6 hours" since this is not true for other application 
times. 
The information was added. 
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Reviewer #2 
This is a very well-written and structured research article which contains interesting data for 
researchers and scientists in the area of dermal and transdermal drug delivery. The 
investigation of the combination of chitosan microparticles and iontophoresis is an intelligent 
approach. The experimental design is sophisticated and neatly arranged. Therefore, it is a 
valuable and excellent contribution to the journal. Since these are interesting results and the 
main focus of the journal Colloids and Surfaces B: Biointerfaces is the impact of colloid and 
interfacial phenomena on biological systems the authors could discuss the causes and 
theoretical fundamentals of the significant accumulation of the chitosan microparticles also 
after the application of iontophoresis in the hair follicles. The physicochemical properties of 
the chitosan particles and their impact on the preferential follicular penetration might be taken 
into account for this discussion in more detail. 
The authors thank the reviewer for these positive comments. The Discussion has now 
been supplemented (see yellow highlighted text) with further information concerning how the 
preferential follicular penetration of the drug is influenced by the physicochemical properties 
of the microparticles and of the drug (i.e., the swelling of microparticles in contact with the 
ethanol/water formulation, the sustained MXS release achieved, and MXS ionization at the 
pH of formulation).  
 
One comment on the physical stability of these particles might be added in section 2.3. How 
and to which amount were the microparticles suspended in the ethanol:water mixture? 
Supplementary information has been added to section 2.3 in response to this 
comment (p. 5). The drug loading efficiency of the chitosan microparticles was at least 80%. 
The amount of chitosan relative to MXS was 2:1 (w/w); 7.5 g of the MXS-loaded 
microparticles were suspended in 93 mL of ethanol/water (6:4 v/v), creating a formulation 
containing 2% w/v of MXS. 
*Graphical Abstract (for review)
Highlights 
 The feasibility of targeting minoxidil sulphate to hair follicles by a combination 
of microencapsulation and iontophoresis was evaluated. 
 Microencapsulation of MXS resulted in a 6-fold increased drug accumulation in 
the hair follicles relative to delivery from a simple MXS solution after 6 hours 
 Application of iontophoresis enhanced follicular delivery for both the solution 
and the microparticle formulations 
 Microencapsulation and iontophoresis can act synergistically to enhance topical 
drug targeting to hair follicles 
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ABSTRACT 
The feasibility of targeting drugs to hair follicles by a combination of microencapsulation 
and iontophoresis has been evaluated. Minoxidil sulphate (MXS), which is used in the 
treatment of alopecia, was selected as a relevant drug with respect to follicular 
penetration. The skin permeation and disposition of MXS encapsulated in chitosan 
microparticles (MXS-MP) was evaluated in vitro after passive and iontophoretic 
delivery. Uptake of MXS was quantified at different exposure times in the stratum 
corneum (SC) and hair follicles. Microencapsulation resulted in increased (6-fold) drug 
accumulation in the hair follicles relative to delivery from a simple MXS solution. 
Application of iontophoresis enhanced follicular delivery for both the solution and the 
microparticle formulations. It appears, therefore, that microencapsulation and 
iontophoresis can act synergistically to enhance topical drug targeting to hair follicles. 
 
Keywords: microparticle; iontophoresis; chitosan; minoxidil sulphate; hair follicle; 
topical drug delivery. 
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1. Introduction 
Polymeric micro- and nanoparticles have been considered as vehicles for topical drug 
delivery due, at least in part, to their potential to protect unstable active ingredients and 
to provide sustained release over prolonged periods of time [1–5]. In addition, the use 
of such particles to target drugs to the hair follicles has been much debated [4–10], with 
their accumulation around the openings of hair follicles predicted to permit sustained, 
localized delivery to these skin appendages. This targeted drug delivery would offer 
potentially improved treatment of diseases such as acne and alopecia. However, while 
the association of particulate drug carriers to follicular openings has been clearly 
visualized in a number of reports in the literature [6–8], there is little quantitative 
evidence to support the contention that microencapsulation effectively enhances drug 
targeting to the hair follicles. 
The skin disposition of micro- and nanoparticles remains a controversial issue. For 
example, Campbell et al. [10] used confocal microscopic skin imaging to demonstrate 
that polystyrene nanoparticles (ranging in size from 20 to 200 nm) did not penetrate 
beyond the most superficial layer of the skin [the outermost few microns of the stratum 
corneum (SC)] even when the skin had been modestly compromised. In contrast, 
Patzelt et al. [8] have claimed that particles of 640 nm diameter penetrated deeper (by 
about 1000-1200 μm) into hair follicles than those of smaller size (122 nm). In neither 
of these examples, nor in any other related study, was the delivery of an encapsulated 
active into the hair follicles, relative to its uptake into the SC, determined as a function 
of time. Such quantification of the skin disposition of the active, of course, is essential 
for any insight into the targeting efficiency of these micro/nanoparticle formulations. 
With respect to iontophoresis, on the other hand, the significant contribution of the 
follicular pathway to topical drug delivery is well documented [11-14]. Iontophoresis 
employs a small electric current (≤ 0.5 mA/cm2) to increase and control drug delivery 
into and through the skin [15] and the lower electrical resistance of the appendegeal 
path explains the increased involvement of this route during electro-transport [11–14]. 
We have previously described the ability of iontophoresis to target minoxidil sulphate 
(MXS) to the follicular route in vitro and in vivo. The anodal iontophoresis of this active, 
which is used to treat alopecia, increased by 5-fold the amount of drug reaching the 
follicular infundibula when compared with passive delivery [16]. Although the 
application of iontophoresis to enhance the overall skin permeation of lipophilic drugs 
encapsulated in 100 nm nanoparticles was recently examined [17–19], its use to 
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improve the follicular targeting of drugs encapsulated in microparticles has not yet been 
investigated. 
In this context, the goal of the research described in this paper was to evaluate whether 
the combination of iontophoresis and microencapsulation would facilitate and enhance 
MXS delivery specifically to the hair follicles. The positively charged drug was chosen 
because of its therapeutic relevance and because its follicular targeting is anticipated to 
result in improved therapeutic efficacy. Chitosan was used to encapsulate MXS 
because of its low cost, biodegradability and non-immunogenicity. Further, chitosan is 
a cationic polymer that forms positively charged microparticles [2], a favorable feature 
for anodal iontophoresis. 
 
2. Materials and Methods 
2.1 Materials 
MXS (99%) was kindly provided by Galena Química e Farmacêutica Ltda. (Campinas, 
Brazil). Chitosan (medium molecular weight, 75-85% of deacetylation), silver wire 
(99.99%, ø = 1.5 mm), silver chloride (99.99%) and platinum wire (ø = 1.0 mm) were 
purchased from Sigma-Aldrich (Steinheim, Germany). HEPES and NaCl were from 
Acros (Berkeley, NJ, USA). HPLC grade methanol, ethanol and acetonitrile were 
purchased from Fisher Scientific (Leicestershire, UK), and acetic acid was obtained 
from Fluka (Steinheim, Germany). The water used in the preparations of all solutions 
was of Milli-Q grade (Millipore, Illkirch-Graffenstaden, France). 
 
2.2 Skin 
Porcine skin was obtained less than 1 hour post-sacrifice from a local abattoir. The 
whole skin was removed from the abdominal region of the animal, separated from the 
underlying fascia, dermatomed to a nominal thickness of 700 µm, and stored frozen at -
20oC for a maximum of six months before use. 
 
2.3 Preparation of MXS loaded chitosan microparticles (MXS-MP) 
MXS-MP were prepared as previously described [2]. Briefly, 3 g chitosan and 1.5 g 
MXS were dissolved in 200 mL of an aqueous solution of 1% (w/v) acetic acid at pH 
4.0. This solution was then spray-dried with a 1.0 mm pressurized atomizer at a feed 
rate of 6 mL/min, and atomizing airflow rate of 6 m3/min (Labmaq model MSD 0.5 spray 
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dryer, Ribeirão Preto, Brazil). The inlet and outlet temperatures were maintained at 
135°C and 75–80°C, respectively. Post-preparation, the microparticles were kept at 
room temperature in a closed container until use. The spherical microparticles had a 
mean (± S.D.) diameter of 3.0 (± 1.5) µm and a zeta potential of +5.9 (± 5.2) mV; the 
drug loading efficiency of the chitosan microparticles was at least 80%. [2]. The amount 
of chitosan relative to MXS was 2:1 (w/w); 7.5 g of the MXS-loaded microparticles were 
suspended in 93 mL of ethanol/water (6:4 v/v), creating a formulation containing 2% 
w/v of MXS. 
 
2.4 Passive drug delivery 
The skin was thawed and mounted in a vertical Franz diffusion cell (area = 0.8 cm2). 
The donor compartment was filled with 1 mL of either a suspension of MXS-MP in 
ethanol-water (pH 5.5), or free MXS dissolved in the same vehicle (the control). Both 
formulations contained 2% w/v MXS. The donor compartment was closed with 
Parafilm® to minimize solvent evaporation. The receptor chamber was filled with a 
physiological buffer (pH 7.4) containing 25 mM HEPES and 133 mM NaCl and was 
magnetically stirred throughout the experiment. 
Permeation experiments (n = 4-5) were performed with each of the formulations (MXS-
MP or free MXS), over periods of 3, 6, 9, 12, 18 and 24 h, so that the kinetics of MXS 
delivery and skin disposition could be characterized. At the end of the experiments, the 
amounts of MXS present in the SC, the hair follicles and the receptor solution were 
quantified. For the SC and follicles, a differential tape stripping technique was 
employed (see section 2.7). 
 
2.5 Iontophoretic drug delivery 
These experiments (n = 3) were conducted following a similar procedure to that 
described above except that a direct constant current of 0.4 mA (0.5 mA/cm2) was 
applied (in this case for 3 hours only) and flow-through iontophoretic cells (LG-1088-IC- 
Laboratory Glass Apparatus Inc., Berkeley, CA, USA) were used. The iontophoretic 
current was passed between Ag/AgCl electrodes prepared as previously described [20] 
via a power supply (Kepco APH 500DM Power Supply, Toronto, Canada). At the end of 
iontophoresis, the amounts of MXS in the SC, hair follicles and receptor solution were 
again determined (see section 2.7). 
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2.6 Post-iontophoresis passive drug delivery 
In a further series of experiments (n = 4), iontophoresis was carried out for 3 hours 
using the MXS-MP formulation and then stopped. Subsequently, the formulation was 
left in contact with the skin for an additional 3, 6 or 12 h, following which the amounts of 
MXS in the SC, hair follicles and receptor solution were determined (see section 2.7). 
 
2.7 Differential tape stripping of MXS 
The follicular and SC uptake of MXS was determined using differential tape-stripping. 
This methodology combines tape-stripping with cyanoacrylate skin surface biopsies 
[21]. The skin was removed from the diffusion cell and placed onto a flat board with the 
SC facing up. The residual formulation was cleaned from the SC surface with an 
isopropanol-soaked gauze pad and the skin was then tape-stripped 15 times, using 
Scotch Book Tape No. 845 (3M, St Paul, MN). The glistening, exposed viable layers of 
the epidermis suggested that complete removal of the SC had been achieved by this 
procedure. The amount of MXS in the tapes was determined by analytically (see 
section 2.8) after a 12-hour extraction of the drug with methanol. 
Subsequent to SC removal, a drop of cyanoacrylate superglue (Henkel Loctite, Dublin, 
Ireland) was applied to the stripped skin area and covered with a further tape-strip 
using light pressure. After total polymerization of the glue (~5 minutes), the tape-strip 
was removed. This provided a biopsy containing follicular casts [21] from which MXS 
was extracted with methanol and quantified (see section 2.8). The efficiency of 
recovery of MXS from the SC and the follicular material was 94 ± 1% and 87 ± 2% [16], 
respectively. 
 
2.8 MXS analysis 
MXS in the methanolic skin and follicular cast extraction samples was assayed by 
HPLC with mass spectrophotometric detection (LCMS-2010 EV, Shimadzu, Kyoto, 
Japan). 5 µL samples were eluted with a mobile phase comprising water - acetic acid - 
acetonitrile (70:0.1:30 v/v; pH 3.3) pumped a flow rate of 1.0 mL/min in a reverse-
phase column (4.0 x 125.0 mm, 5 µm, from Dionex Co., Salt Lake City, UT, USA). 
Detection was performed in positive ion mode (1.65 kV, m/z = 210.05). The calibration 
curve was linear (r = 0.99), over the concentration range 0.05 to 1.00 µg/mL. The LOQ 
and LOD were 0.05 and 0.005 µg/mL, respectively. 
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MXS in the aqueous receptor solution samples contained a considerable amount of 
salt, which could influence the mass detection, and hence was quantified by reverse-
phase HPLC. 10 µL aliquots of the samples were injected into a liquid chromatograph 
(LC-2010A HT, Shimadzu, Kyoto, Japan) equipped with an automatic sample injector 
and the same reverse-phase column. The mobile phase was water - acetic acid - 
acetonitrile (30:0.1:70 v/v; pH 3.3) pumped a flow rate of 1.0 mL/min. MXS was 
detected by UV absorbance at 285 nm. The calibration curve was linear (r = 0.99) 
again over the concentration range of 0.05 to 1.00 µg/mL. The LOQ and LOD were 
0.05 and 0.005 µg/mL, respectively. 
 
2.9 Statistical analysis of the data 
Three to five replicates of each transport experiment were performed. Results are 
presented as mean ± standard deviation (SD) and expressed in terms of the quantity of 
MXS per unit area of skin (µg/cm2). Skin permeation fluxes (µg/cm2/h) and lag times 
were determined from the slopes and intersection of the linear section of the plot of 
cumulative amount of MXS permeated (µg/cm2) as a function of time (h), respectively. 
Differences between the passive penetration of MXS (µg/cm2) from the microparticle 
formulation and the control solution were assessed by a parametric t-test.  When 
comparing the passive and iontophoretic delivery of MXS from the microparticles with 
the drug’s simple diffusion from the control solution, an ANOVA followed by Tukey’s 
test was used. Statistical significance was fixed at p < 0.05. 
 
3. Results and Discussion 
The skin disposition and percutaneous absorption of MXS following passive drug 
delivery from either a simple solution or the microparticle suspension is shown in 
Figure 1 (and in Supplementary Table 1). The amount of drug that penetrated the skin 
into the receptor solution increased in the normal way as a function of time, with slightly 
more than double the quantity being absorbed from an aqueous solution as compared 
to that from the microparticle formulation (Figure 1a); the apparent steady-state fluxes 
of 2.08 (± 0.11) and 0.87 (± 0.15) μg/cm2/h, respectively, were significantly different (p 
< 0.05).  These results are consistent with the microparticles remaining on skin surface, 
and that it is only the drug, which has been released in a sustained manner from the 
carriers, that is able to cross the skin.  
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The SC and follicular uptakes of MXS, determined by the differential stripping 
technique, when delivered from the control solution and from the microparticles, are 
presented in Figure 1b. The levels of drug recovered in the SC tape-strips exhibit no 
clear trend. At 8, 12 and 18 hours, there is no obvious difference in the uptake from the 
two formulations; on the other hand, at 3 and 6 hours, and at 24 hours, the MXS 
recovered in the SC was apparently significantly, though less than 2-fold, higher (p < 
0.05) from the control solution. In contrast, follicular delivery was consistently [and, 
again, significantly (p < 0.05)] greater from the microparticle suspension, a difference of 
nearly 5-fold being achieved at 6 hours. As previously reported [2], chitosan MXS-MP 
particles do indeed swell quickly in contact with ethanol/water (from 3.0 µm to 5.7 µm) 
and they release MXS efficiently thereafter (approximately 30%, 53%, and 72% after 3, 
6 and 12 h, respectively [2]).  It is reasonable to assume that these swollen 
microparticles remain on skin surface, being unable to cross the skin themselves. 
However, the microparticles appear to accumulate in follicular openings, a conclusion 
supported by the enhanced recovery of MXS from these appendageal structures.  
Notably, the quantities of MXS recovered from the follicles were appreciably smaller 
than those found in the SC. However, when the differential surface areas available for 
SC and follicular transport are taken into account (i.e., the follicles are typically 
estimated to occupy only 0.09-1.28% of the total skin surface [22]), it is clear that the 
microencapsulation of the drug has dramatically improved the efficiency with which it 
has reached (or been targeted to) the follicles. Furthermore, it may be anticipated that 
this finding would be even more significant in human scalp skin (as compared to the 
porcine abdominal tissue used here) where the follicular density is approximately an 
order of magnitude higher (240 follicles/cm2 compared to about 20 in the pig [23,24]). 
Previously, it has been shown [16] both in vitro and in vivo that the follicular delivery of 
MXS from an aqueous formulation was increased by the application of iontophoresis. 
Because the chitosan-based MXS-MP have a positive zeta potential [2], it was 
hypothesised that an iontophoretic current would enhance follicular localisation when 
the drug delivery system was associated with the anode (and also permitting 
advantage to be taken of the anode-to-cathode electroosmotic flow typically 
established across the net negatively-charged skin membrane [15]).  At the pH of the 
formulation (pH ~5.5), MXS is 90% non-ionized suggesting that its enhanced, 
electrotransport-mediated delivery will be due to a combination of electrorepulsion and 
electroosmosis [16].  Experiments were performed, therefore, in which the passive data 
discussed already were compared to results obtained when the formulations (solution 
control and MXS-MP) were subjected to a 3-hour period of anodal iontophoresis. MXS 
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permeation to the receptor phase, as well as SC and follicular uptake, were determined 
both immediately post-application of current, and (for MXS-MP) as a function of time 
over the next 12 hours with no current applied but with the formulation remaining in 
contact with the skin. 
Figure 2 (and Supplementary Table 1) shows the disposition of MXS at the end of 3 
hours of iontophoresis following application of the solution control and microparticle 
formulations, and includes the corresponding passive data for reference. Clearly, 
iontophoresis increased MXS delivery from both the control solution and the 
microparticles both into the SC and, even more dramatically, into the follicles and 
across the skin. However, when comparing the two formulations with iontophoresis, 
there was no significant difference (p > 0.05) in either SC uptake or permeation of 
MXS; only for follicular targeting was MXS delivery significantly better (p < 0.05) with 
iontophoresis from the microparticle vehicle (3.9 ± 0.3 µg/cm2 compared to 2.4 ± 0.6 
µg/cm2 from a simple solution). For both formulations, though, the relative 
enhancement in follicular uptake achieved by the application of current was 6- to 8-fold, 
with the improved bioavailability being achieved more rapidly as well.  
Even with iontophoresis, the microparticles used are too large to be transported, to any 
significant extent, through the skin by the applied electric field.  However, because the 
follicles are low resistance pathways for the movement of charge across the skin [11-
14], we speculate that iontophoresis can quickly and efficiently target MXS-MP to 
follicular openings, and that MXS is then released from the microparticles directly into 
the infundibulum. As stated above, we believe that only drug that has been released 
from the microparticles is able to cross the skin (with or without iontophoresis); 
nevertheless, because iontophoresis ‘targets’ the MXS-MP to the follicles, increased 
levels of drug are made available to be taken up and absorbed at these specific sites.  
From a practical standpoint, for the topical treatment of alopecia, where a local effect is 
desired with as little transdermal exposure as possible, the judicious selection of 
current density and application time in vivo is required for optimal therapy.  
MXS disposition following 3 hours of iontophoresis of the microparticle formulation was 
then assessed over the next 12 hours (while leaving the formulation in contact with the 
skin). These experiments were able to shed light on whether the apparently enhanced 
deposition of microparticles into hair follicle openings could sustain MXS delivery post-
iontophoresis. The results are shown in Figure 3. While the permeation of MXS to the 
receptor phase continued to increase with time (a finding not unexpected as the MXS-
MP were left in contact with the skin once the current had been turned off), the levels of 
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drug in the SC and, crucially, in the follicles remained essentially unchanged, 
supporting the continued availability of the drug close to the therapeutic target. 
 
4. Conclusion 
The encapsulation of MXS in chitosan microparticles (MXS-MP) in vitro after passive 
delivery resulted in increased (6-fold) drug accumulation in the hair follicles relative to 
delivery from a simple MXS solution. Application of iontophoresis further enhanced 
follicular delivery from both the solution and the microparticle formulations.  The 
amount of MXS taken up into follicles after iontophoresis of microparticles was 
significantly greater (p < 0.05) compared to that from a simple MXS solution. We 
consider that this important enhancement in MXS follicular retention together with the 
sustained release of the drug when iontophoresis is combined with microparticles 
represents a potentially useful strategy for the targeted treatment of alopecia.  
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Figures Legends 
 
Figure 1. Percutaneous absorption and skin disposition of MXS as a function of time 
after passive delivery from either an aqueous solution (control) or from a microparticle 
suspension. (a) Skin permeation of MXS into the receptor phase. (b) SC and follicular 
uptakes of MXS (left and right hand y-axes, respectively). 
 
Figure 2. Percutaneous absorption and skin disposition of MXS as a function of time 
after 3 hours of iontophoresis or passive delivery from either an aqueous solution 
(control) or from a microparticle suspension (mean ± SD of 3 replicates). 
 
Figure 3. MXS levels permeated to the receptor phase, and localized in the SC and 
hair follicles as a function of time post 3 hours of iontophoresis following application of 
MXS-MP (values are mean ± SD of 4 replicates). 
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